IP Library Granted Patent US 9,643,925
Granted Patent B2
US 9,643,925 · App. 14/837,201 · Granted May 9, 2017

Compounds, compositions and methods

Inventors: Bradley Paul Morgan (South San Francisco, CA); Alex Muci (San Francisco, CA); Pu-Ping Lu (South San Francisco, CA); Erica Anne Kraynack (Belmont, CA); Todd Tochimoto (South San Francisco, CA); David J. Morgans, Jr. (South San Francisco, CA)
C07D213/75C07D211/56C07D239/42C07D261/14C07D263/48C07D271/113C07D295/26C07D401/10C07D401/12C07D417/00C07D417/10C07D417/12C07D487/04C07D491/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,643,925
App. No.
14/837,201
Granted
May 9, 2017
Kind
B2
Abstract

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Claims (34)

1. A method of preparing a compound of Formula I

comprising the steps of

contacting a compound of Formula 400 with sodium cyanide, and nickel (II) bromide

to form a compound of Formula 401;

reducing the compound of Formula 401 in the presence of a reducing agent to form a compound of Formula 402

wherein R is chosen from O and NH;

contacting a compound of Formula 402 with a reducing agent and a compound of formula R 1 —H wherein R 1 is optionally substituted amino or optionally substituted heterocycloalkyl to form a compound of Formula 403; and

contacting a compound of Formula 403 with a compound of the formula R 2 —NCO to yield a compound of Formula I:

wherein

n is one;

W, X, Y, and Z are independently —C═ or —N═, provided that no more than two of W, X, Y, and Z are —N═;

R 2 is optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl or optionally substituted heterocycloalkyl,

R 3 is hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl when W is —C═, and R 3 is absent when W is —N═;

R 4 is hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl when Y is —C═, and R 4 is absent when Y is —N═; and

R 5 is hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl when X is —C═, and R 5 is absent when X is —N═;

R 13 is hydrogen, halo, cyano, hydroxyl, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl when Z is —C═, and R 13 is absent when Z is —N═; and;

R 6 and R 7 are each hydrogen.

2. The method of claim 1 , wherein each of W, X, Y, and Z are —C═.

3. The method of claim 2 , wherein R 13 is F, and each of R 3 , R 4 , and R 5 is hydrogen.

4. The method of claim 1 , wherein R 2 is optionally substituted heteroaryl.

5. The method of claim 3 , wherein R 2 is optionally substituted heteroaryl.

6. The method of claim 1 , wherein R 1 is optionally substituted heterocycloalkyl.

7. The method of claim 3 , wherein R 1 is optionally substituted heterocycloalkyl.

8. The method of claim 4 , wherein R 1 is optionally substituted heterocycloalkyl.

9. The method of claim 1 , wherein the sodium cyanide is present in an amount of at least 2 equivalents compared to the amount of the compound of Formula 400.

10. The method of claim 1 , wherein the nickel (II) bromide is present in an amount of at least 1 equivalent compared to the amount of the compound of Formula 400.

11. The method of claim 1 , wherein the reducing agent used to form the compound of Formula 402 comprises diisobutyl aluminum hydride (DIBAL-H).

12. The method of claim 11 , wherein DIBAL-H is present in an amount of at two or more equivalents compared to the amount of the compound of Formula 401.

13. The method of claim 1 , wherein reducing agent used to form the compound of Formula 402 is present in an amount of at least 2 equivalents compared to the amount of the compound of Formula 401.

14. The method of claim 1 , wherein the reducing agent used to form the compound of Formula 403 comprises triacetoxyborohydride.

15. The method of claim 11 , wherein the reducing agent comprises triacetoxyborohydride.

16. The method of claim 1 , wherein the compound of formula R 2 —NCO is present in an amount of 1 equivalent compared to the amount of the compound of Formula 403.

17. The method of claim 1 , further comprising isolating the compound of Formula I.

18. The method of claim 14 , wherein the isolating comprises crystallizing the compound of Formula I, filtering the compound of Formula I, or both.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: MORGAN, BRADLEY PAUL; MUCI, ALEX; LU, PU-PING; TOCHIMOTO, TODD; MORGANS, DAVID J., JR.; KRAYNACK, ERICA ANNE
To: CYTOKINETICS, INCORPORATED
Reel/Frame 057092/0366 →
Continuity (6)
Continuation 14489705 · Sep 18, 2014
Continuation 13946353 · Jul 19, 2013
Continuation 13341413 · Dec 30, 2011
Continuation 11630062
Provisional Application 60581197 · Jun 17, 2004
Related Publication 20160115133A1 · Apr 28, 2016